Drug class
Immunotoxins clinical trials
A class of medicines: the studies that test any of its 7 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the immunotoxins studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
375 studies that test it; most in 2013 (30)
| Year | Studies |
|---|---|
| 2000 | 5 |
| 2001 | 3 |
| 2002 | 9 |
| 2003 | 8 |
| 2004 | 8 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 13 |
| 2008 | 10 |
| 2009 | 14 |
| 2010 | 10 |
| 2011 | 11 |
| 2012 | 21 |
| 2013 | 30 |
| 2014 | 26 |
| 2015 | 26 |
| 2016 | 19 |
| 2017 | 20 |
| 2018 | 24 |
| 2019 | 23 |
| 2020 | 14 |
| 2021 | 17 |
| 2022 | 14 |
| 2023 | 16 |
| 2024 | 10 |
| 2025 | 7 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 105 · Other 271
M.D. Anderson Cancer Center (28) · Hoffmann-La Roche (21) · Seagen Inc. (18) · Pfizer (14) · National Cancer Institute (NCI) (12) · Dana-Farber Cancer Institute (10) · City of Hope Medical Center (9) · Genentech, Inc. (7)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 376
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Brentuximab Vedotin
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06917911Written as Gemtuzumab Ozogamicin
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)RecruitingPhase 3Charite University, Berlin, GermanyNCT07476729Written as Inotuzumab ozogamicin (INO)
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingPhase 2NRG OncologyNCT05408845Written as Trastuzumab Emtansine
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Inotuzumab Ozogamicin
- Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruitingPhase 2PETHEMA FoundationNCT07862946Written as Inotuzumab Ozogamicin (IO)
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as Gemtuzumab Ozogamicin
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07840976Written as Inotuzumab Ozogamicin (IO)
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingPhase 2PfizerNCT05748171Written as Inotuzumab ozogamicin
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05645718Written as Inotuzumab ozogamicin
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingPhase 2City of Hope Medical CenterNCT04561206Written as Brentuximab Vedotin
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Trastuzumab emtansine (T-DM1)
- Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaRecruitingPhase 1/2Leland MethenyNCT03104491Written as Inotuzumab Ozogamicin
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingPhase 2Emory UniversityNCT05039073Written as Brentuximab Vedotin
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3Children's Oncology GroupNCT03959085Written as Inotuzumab Ozogamicin
- ATEMPT 2.0: Adjuvant T-DM1 vs THRecruitingPhase 2Dana-Farber Cancer InstituteNCT04893109Written as trastuzumab-emtansine
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingEarly Phase 1New York Medical CollegeNCT03719105Written as Brentuximab Vedotin
- Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaRecruitingPhase 2University of WashingtonNCT03737955Written as Gemtuzumab Ozogamicin
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Written as T-DM1
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05357794Written as Brentuximab vedotin